PRCT - Wutah pendapatan taun lumaku Procept

PROCEPT BioRobotics generates revenue through the sale of urological robots and associated consumables to clinics. The last twelve months (LTM) revenue growth rate illustrates the market response, with the current level standing at 17.80. Safe prostate treatment methods secure physician confidence, while automated ultrasonic tissue ablation solidifies the company's technological leadership within the surgical robotics sector.

Microchip shortages resulting from geopolitical conflicts directly limit the production of complex surgical systems from PROCEPT BioRobotics (PRCT). The shipment dynamics of these devices determine the percentage change in sales over the last 12 months compared to the previous 12 months. This indicator smooths out market noise, revealing the actual trajectory of the business's annual expansion. The upward trend on this chart confirms management efficiency but warns investors of the risk of an overvalued asset.